Physician Scientist - Medical Oncologist, Drug Development - Digital Health - Tweets my own
Cambridge, MA
Joined March 2012
- Tweets1.6K
- Following3.3K
- Followers1.8K
- Likes1.6K
Charles Ferté retweeted
Paper: nature.com/articles/s41591-0…
Open source code: github.com/zou-group/sleepfm…
Truly wonderful collaboration with Emmanuel Mignot's lab, led by @connect_thapa and Magnus Kjaer! Thanks to all the awesome collaborators👏 n/n
Charles Ferté retweeted
Pan-cancer clinicopathological and genomic characteristics of peritoneal metastasis | npj Precision Oncology nature.com/articles/s41698-0…
Charles Ferté retweeted
If Exercise Were a Pill, We'd All Prescribe It to Patients With Cancer. But It's Not | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO…
Charles Ferté retweeted
📰 Le professeur Benjamin Besse élu à la présidence de l’organisation européenne pour la recherche et le traitement du cancer, l’@EORTC.
Lire le communiqué de presse ➡ gustaveroussy.fr/fr/le-profe…
Charles Ferté retweeted
Our meta-analysis (n=12,698)
shows:
Omitting 5-FU bolus from GI chemo regimens →
✔️ No difference in PFS/OS
📉 Less grade 3–4 neutropenia (OR 0.46)
📉 Less thrombocytopenia (OR 0.53)
@dr_yusufilhan @dr_yakupergun @oncodaily @OncoAlert @Larvol
Charles Ferté retweeted
Esteban Cvitkovic (“Steve”, “El Gordo”) died on June 20, 2025. Inventor of hyperhydrated cisplatin, developer of oxaliplatin, pioneer in head and neck cancers.He had the rare gift of seeing the truth behind appearances and asking:
“Is this practice truly useful to the patient?”
Charles Ferté retweeted
🔬 ADCs in Platinum-Sensitive Ovarian Cancer (PSOC) – Promising but early days 🧵👇
💥 Four ADCs in play:
• 🔗 Sac-TMT: Belotecan payload, TROP2 target
• 💣 Dato-DXd: Deruxtecan payload, TROP2 target
• 🎯 PICCOLO: DM4 payload, FRα target
• 🧬 Raludotug: Deruxtecan payload, CDH6 target
📊 Reported ORRs: 51–72%
🥇 Raludotug leads with 72.2% response (ESMO Gyn)
📌 Median PFS reported only in PICCOLO & Raludotug (~7–8 months)
⚠️ Small sample sizes in Sac-TMT & Dato-DXd arms
🧠 Key questions:
🔹 Prior ADC exposure?
🔹 Biomarker selection strategy?
🔹 Payload redundancy across studies?
🚨 Don't just follow the target—know the payload & DAR too.
#ESMOGynae25 #OncoTwitter #GynOnc #OvarianCancer #ADCs #PrecisionOncology @OncoAlert
Charles Ferté retweeted
Morning > Afternoon for IO?
Evidence is mounting—retrospective and now prospective (210 pts, randomized, PFS HR 0.42 but no PD-L1 strat).
Given IO’s long half-life, maybe only the timing of the first dose matters.
#ASCO2025
Charles Ferté retweeted
Worthy of a plenary session — CO.21 shows that exercise reduces recurrence after adjuvant and improves OS
Charles Ferté retweeted
ADCs: are we dosing them right? Likely not. In this body composition study of 48 patients with mBC receiving T-DXd, higher subcutaneous adipose tissue and higher BMI were associated with a 5-fold increase in dose reductions and reduced T-DXd activity. nature.com/articles/s41523-0…
Charles Ferté retweeted
Social determinants of health (SDOH) are often overlooked in policy-making, leading to individual-focused health initiatives.
In @TheLancetPH, authors call for a shift from individual accountability to systemic solutions to address SDOH: hubs.li/Q03c1Jwt0
Charles Ferté retweeted
The largest medical #AI randomized controlled trial yet performed, enrolling >100,000 women undergoing mammography screening, was published today @LancetDigitalH
The use of A.I. led to 29% higher detection of cancer, no increase of false positives, and reduced workload compared with radiologists without A.I.. thelancet.com/journals/landi…
Charles Ferté retweeted
Researchers paid $8.968 billion for their findings to be freely accessible.
🧵1/10
Charles Ferté retweeted
📖Cancer statistics, 2025. 👉For the first time, the number of newly diagnosed female lung cancer cases has surpassed that of males. 👉This significant increase, particularly among women under the age of 49, is largely driven by diagnoses in young women who have never smoked. Many of these cases are associated with oncogene-driven lung cancer.
acsjournals.onlinelibrary.wi… @lungoncdoc @StephenVLiu @MDAndersonNews @EGFRResisters @YoungLungCancer @Exon20Group @ALKPositiveinc @metcrusaders @jillfeldman4 @acmoorephd
Charles Ferté retweeted
Investors should know how much competition their drug has
Immunology, which remains a hot TA, has intense competition for many targets
Being best-in-class is critically important to stand out
#learnbiotechinvesting #biotech #investing #BiotechPrometheus
Charles Ferté retweeted
Thrilled to see our ADC review online on @CD_AACR!!
…and perfectly timed for the start of #ENASymp24
@PTarantinoMD @VriesElisabeth @AACRPres
aacrjournals.org/cancerdisco…
Charles Ferté retweeted
🔬La semaine dernière à la #SIOG2024 : présentation en session plénière de @Resilience par @drnicober mettant en lumière la faisabilité de la télésurveillance dans la pratique clinique chez les populations âgées (> 65 ans).
Un grand merci à l'ensemble des auteurs ! 🙏
Charles Ferté retweeted
Wonderful #ESMO24 sessions in Barcelona: good science, practice changing trials results, friendships and networking #CancerCare #UCOM @GustaveRoussy @GroupeUnicancer
Charles Ferté retweeted
⭐️Leading Causes of Death in the US, 2019-2023. Interesting how the #healthcare landscape has changed in 4 yrs. Cancer remains the 2nd leading cause of death after heart disease @JAMAOnc @JAMA_current @oncodaily
jamanetwork.com/journals/jam…
